BIOLASE, INC Form 4 July 03, 2017

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION $\,$ ON

OMB APPROVAL

OMB
3235-0287

Check this box if no longer subject to

Washington, D.C. 20549

Number: January 31,

subject to
Section 16.
Form 4 or
Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires. 2005
Estimated average burden hours per response... 0.5

5. Relationship of Reporting Person(s) to

Form 5 obligations may continue. *See* Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

1(b).

Stock

(Print or Type Responses)

1. Name and Address of Reporting Person *

CLARK PAUL N			Symbol					Issuer				
			BIOLA	BIOLASE, INC [BIOL]					(Check all applicable)			
(Last)	(First)	(Middle)	3. Date of	f Earliest T	ransaction			(3 a. a. p.				
4 CROMWELL				(Month/Day/Year)				_X_ Director 10% Owner Officer (give title Other (specify				
			06/30/2	017				below) below)				
	(Street)		4. If Ame	endment, Da	ate Original			6. Individual or Jo	oint/Group Filir	ng(Check		
	Filed(Month/Day/Year)					Applicable Line) _X_ Form filed by One Reporting Person						
IRVINE, C	A 92603								More than One Re			
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative S	ecuriti	ies Acq	cquired, Disposed of, or Beneficially Owned				
1.Title of	2. Transaction Da			3. T	4. Securitie			5. Amount of	6. Ownership	7. Nature of		
Security (Instr. 3)	(Month/Day/Year	any	on Date, if	Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5)				Securities Beneficially	Indirect Beneficial			
		(Month	/Day/Year)	(Instr. 8)				Owned	(D) or	Ownership		
						(4)		Following Reported	Indirect (I) (Instr. 4)	(Instr. 4)		
						(A) or		Transaction(s)				
				Code V	Amount	(D)	Price	(Instr. 3 and 4)				
Common	06/30/2017			С	156,300	٨	\$ 1.24	1,311,557	I	By Trust		
Stock	00/30/2017			C	130,300	A	(1)	1,311,337	1	(2)		
							_			See		
Common								221,200	I	Footnote		
Stock								,		(3)		
Common								06.250	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form SEC 1474 (9-02)

D

96,250

Edgar Filing: BIOLASE, INC - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D Participating Convertible Preferred Stock (4)	\$ 1.24	06/30/2017		С		1,563	06/30/2017	(5)	Common Stock	156,300

Reporting Owners

Reporting Owner Name / Address	Relationships						
r g	Director	10% Owner	Officer Other				
CLARK PAUL N							
4 CROMWELL	X						
IRVINE, CA 92603							

Signatures

/s/ Michael C. Carroll, attorney-in-fact for Paul N.

Clark 07/03/2017

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On June 30, 2017, as a result of receipt of the Requisite Stockholder Approval (defined and described further in the Securities Purchase

 Agreement dated April 11, 2017 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on April 14, 2017), each share of Preferred Stock (as defined below) automatically converted into 100 shares of Common Stock, reflecting a conversion price equal to \$1.24 per share.
- (2) The Common Stock is held directly by the Paul and Carolyn Clark Revocable Trust of 2009. Mr. Clark is the trustee of the Paul and Carolyn Clark Revocable Trust of 2009.
- (3) The Common Stock is held directly by PNC Investments LLC. Mr. Clark is the sole managing member of PNC.
- (4) These shares of Series D Participating Convertible Preferred Stock ("Preferred Stock") were acquired by the Paul and Carolyn Clark Revocable Trust of 2009 in a private placement with the Issuer, which closed on April 18, 2017.

Reporting Owners 2

Edgar Filing: BIOLASE, INC - Form 4

- (5) The Preferred Stock had no expiration date.
- (6) The Preferred Stock was held directly by the Paul and Carolyn Clark Revocable Trust of 2009. Mr. Clark is the trustee of the Paul and Carolyn Clark Revocable Trust of 2009.
- The Reporting Person disclaims beneficial ownership of the Preferred Stock except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the Preferred Stock for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.